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Abstract
Objectives: Effective chemoprevention strategies exist for women at high risk for breast cancer,
yet uptake is low. Physician recommendation is an important determinant of uptake, but little is
known about clinicians' attitudes to chemoprevention.
Methods: Focus groups were conducted with clinicians at five Family Cancer Centers in three
Australian states. Discussions were recorded, transcribed and analyzed thematically.
Results:  Twenty three clinicians, including genetic counselors, clinical geneticists, medical
oncologists, breast surgeons and gynaecologic oncologists, participated in six focus groups in 2007.
The identified barriers to the discussion of the use of tamoxifen and raloxifene for
chemoprevention pertained to issues of evidence (evidence for efficacy not strong enough, side-
effects outweigh benefits, oophorectomy superior for mutation carriers), practice (drugs not
approved for chemoprevention by regulatory authorities and not government subsidized,
chemoprevention not endorsed in national guidelines and not many women ask about it), and
perception (clinicians not knowledgeable about chemoprevention and women thought to be
opposed to hormonal treatments).
Conclusion:  The study demonstrated limited enthusiasm for discussing breast cancer
chemoprevention as a management option for women at high familial risk. Several options for
increasing the likelihood of clinicians discussing chemoprevention were identified; maintaining up
to date national guidelines on management of these women and education of clinicians about the
drugs themselves, the legality of "off-label" prescribing, and the actual costs of chemopreventive
medications.
Introduction
Effective chemoprevention strategies are now available for
women at increased risk for breast cancer [1]. This repre-
sents a major addition to the risk management options for
such women, particularly those who choose to avoid or
postpone risk-reducing surgery. However, uptake of breast
cancer chemoprevention is low in women at high familial
risk [2-5]. The reasons for this low uptake must be eluci-
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dated with priority if the promise of chemoprevention to
reduce morbidity from breast cancer is to be fulfilled.
Four randomized controlled trials involving over 25,000
women at increased risk have demonstrated that
tamoxifen taken daily for 5 years reduces breast cancer risk
by 30–50% [6-9]. The preventive effect is sustained for at
least five years after cessation of therapy [9] and the risk of
serious side-effects is low, particularly for premenopausal
women [10,11]. Raloxifene is an alternative option for
postmenopausal women. It is as effective as tamoxifen in
preventing invasive breast cancer somewhat less effective
in preventing in situ cancers [12] and has a superior side-
effect profile particularly with regard to gynaecological
side-effects and thrombosis. Both drugs predominantly
reduce incidence of estrogen receptor positive tumors.
There are no data on the potential efficacy of Raloxifene for
chemoprevention in BRCA1 and BRCA2 mutation carriers
and limited data for tamoxifen. Breast cancers arising in
BRCA1 mutation carriers are estrogen receptor negative in
80–90% of cases, conversely those arising in BRCA2 muta-
tion carriers are usually estrogen receptor positive [3] In the
NSABP-P1 chemoprevention trial [13] the estimated risk
ratios for BRCA1 and BRCA2 mutation carriers who took
tamoxifen versus placebo were 1.67 (95% confidence inter-
val 0.32–10.7) and 0.38 (95% confidence interval 0.06–
1.56) respectively. The number of mutation carriers who
developed breast cancer in this study were very small (8
BRCA1 and 11 BRCA2), so the confidence intervals are
wide and the results difficult to interpret. However a retro-
spective study demonstrated a 50% reduction in risk of
contralateral breast cancer for both BRCA1 (odds ratio =
0.50: 95% CI, 0.30–0.85) and BRCA2 (odds ratio = 0.42:
95% CI, 0.17–1.02) mutation carriers who took tamoxifen
after their first breast cancer. Also in that study, the protec-
tive effect of tamoxifen was not seen for mutation carriers
who had undergone oophorectomy (odds ratio = 0.83:
95%CI, 0.24–2.89), but that subgroup was small and so
the question of whether tamoxifen confers additional pro-
tection against breast cancer in mutation carriers who have
undergone oophorectomy remains controversial.
The type of provider whom patients see for genetic testing
has been found to contribute to variations in prophylactic
treatment [14]. Physician recommendation is an impor-
tant determinant of uptake of breast cancer chemopreven-
tion[15,16]. Whether a physician informs the client of the
option of chemoprevention, the strength of the recom-
mendation [17] and the framing of the information [18]
might all be expected to influence uptake of chemopre-
vention. Although surveys of physicians to determine che-
moprevention prescribing rates have been conducted in
North America, few examined the reasons for the low rates
[19,20]. Qualitative method is particularly suited to
answering this question as the variables influencing pre-
scribing have not yet been identified [21].
In Australia, there is a network of Family Cancer Centers
(FCCs), funded by State governments, that does the vast
majority of assessment and genetic testing of women at
high familial risk for breast cancer. A prior Australian
study undertaken between 1998 and 2000, demonstrated
that FCC clinicians discussed chemoprevention in 58% of
pre-genetic testing consultations, although most discus-
sions (41%) were focused on a chemoprevention trial
[22]. The purpose of the current study was to identify and
explore the contemporary barriers and enablers to clini-
cians discussing and/or recommending chemoprevention
in their client consultations in the setting of FCCs. Focus
group method was chosen as it was more likely to reveal
areas of shared understanding and areas of dispute among
FCC clinicians than individual interviews and is more
reflective of the multidisciplinary approach to care used in
the clinics. Focus groups also create a more relaxed envi-
ronment for participants as the group is under study
rather than the individual [21].
Methods
The study population was clinicians working in any one of
five FCCs in one of three Australian capital cities. In the
two cities in which there was more than one Center oper-
ating, the two largest Centers were selected. Clinicians,
including clinical geneticists, genetic counselors, medical
oncologists, breast surgeons, breast physicians and gynae-
cologic oncologists, were eligible for the study if they pro-
vided risk management advice to women at high risk for
breast cancer. A contact person at each Center, usually the
Director, determined the eligibility of the clinicians at that
Center. For some Centers, genetic counselors were consid-
ered eligible, while for others, only physicians were eligi-
ble. The decision depended on clinic protocols for the
provision of risk management advice, and was not ques-
tioned by the researchers.
The time and location of the focus groups was negotiated
with the contact person at each Center. A participant
information sheet, and invitation to a focus group on the
provision of risk management advice was e-mailed to eli-
gible clinicians by the contact person. Focus groups were
facilitated by LK, using a list of prompts and two case stud-
ies (Figure 1). Initially, participants were asked to describe
the FCC, the role of clinicians, and the average client and
their pathway through the FCC and beyond. Case studies
were then used to identify more specific information
about risk management and each intervention was dis-
cussed. The discussion was tape recorded, transcribed, de-
identified and analyzed thematically.Hereditary Cancer in Clinical Practice 2009, 7:9 http://www.hccpjournal.com/content/7/1/9
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Transcripts were read to identify the main themes. All rel-
evant data was then coded under one or more of the
themes and each theme analyzed by two researchers (KAP
& LK) to ensure reliability. The study was approved by the
Human Research and Ethics Committees (HREC) at each
recruiting institution. Written informed consent from the
participating clinicians was only considered necessary by
the HREC at one site. For the other sites, attendance at the
focus group session was considered to represent implied
consent.
Results
Twenty three of 36 eligible clinicians participated in six
focus groups, (3 to 5 participants per group) between
April and August 2007. Participant characteristics are
summarized in Table 1. Two thirds of participants were
women, and a range of specialties were represented.
Three main codes were identified from the data; 1) 'Per-
ception of role' (how clinicians described their role in the
management of high risk women) 2) 'Case study one' (all
discussion in response to case study one), 3) 'Chemopre-
vention' (all discussion of chemoprevention either in
response to case studies or to any other question, includ-
ing the specific question "with whom do you discuss che-
moprevention?"). The 'Case study one' and
'Chemoprevention' codes were analyzed for this report.
The analysis identified both the similarities and differ-
ences in response to case study one, and the barriers and
enablers to the discussion of chemoprevention.
Case Study 1
Participants discussed how they would advise the woman
in Case Study 1. Prior to tailoring a risk management strat-
egy, participants said they would outline the options
available. The range of options potentially discussed were
screening (mammography, MRI, ultrasound, clinical
breast exam), lifestyle modifications, surgery (mastec-
tomy and bilateral salpingo-oophorectomy (BSO)) and/
or chemoprevention (Tamoxifen or Raloxifene). Mostly,
clients leave the FCC with a personalised strategy which is
discussed with them, and reiterated in a subsequent letter.
Clients are then expected to execute their risk manage-
ment strategy either through regular attendance at a Risk
Management Clinic (only available in selected Centers)
[23], or through their family doctor or specialist.
The process of devising a management strategy was sum-
marised by 2C (breast surgeon): 'All of these things are on
the table at the first instance, for discussion. Then people will
make up their mind down which path they want to travel'. In
Hypothetical scenarios and an example of prompts used in focus group discussions Figure 1
Hypothetical scenarios and an example of prompts used in focus group discussions.
Case study 1:   A 45 year old woman with 3 first degree relatives with breast 
cancer and a second degree relative with ovarian cancer and a 
documented BRCA2 mutation. What would you discuss?
Case study 2:  A 45 year old woman with 1 first degree relative with breast 
cancer at age 55. What would you discuss?
Prompts:  With whom do you discuss chemoprevention?  
What do you say? 
  With whom would you NOT discuss chemoprevention?  
 Why  not?
Table 1: Characteristics of participants
Specialty Number
Genetic Counselor 4
Clinical Geneticist 5
Medical Oncologist/Fellow 10
Breast Physician/Surgeon 3
Gynecologic Oncologist 1
Gender
Male 7
Female 16Hereditary Cancer in Clinical Practice 2009, 7:9 http://www.hccpjournal.com/content/7/1/9
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most Centers however, the clinicians would recommend a
preferred strategy. In each Center, the preferred strategy
for Case Study 1 was BSO (Figure 2). Clinicians from 3 of
5 Centers mentioned chemoprevention in the discussion
of options for management of Case Study 1, but clinicians
from 2 Centres stated explicitly that they would not men-
tion it as an option (Figure 2).
Potential candidates for chemoprevention
Focus groups who said they did mention chemopreven-
tion were asked who they discussed it with. Groups 1, 2, 5
and 6 identified mutation carriers, but particularly BRCA2
carriers. 1D (medical oncologist) was the only participant
to suggest that women at high risk without a documented
mutation should also be informed about chemopreven-
tion, with the proviso of 'explaining where the uncertainty
still lies'. Conversely 6D (medical oncologist) said 'BRCA
mutation carriers, particularly BRCA2, I'm not too sure about
high risk women without BRCA mutation ... I would be more
comfortable with just the mutation carrier. I mean, if the high
risk woman raised that I would discuss that...but it may not be
our recommendation to jump in ... and just take it.'.
Barriers to Discussing Breast Cancer Chemoprevention
Analysis of the code 'Chemoprevention' revealed several
barriers and enablers to the discussion of chemopreven-
tion with women at high risk of breast cancer (Tables 2
and 3). Each of the barriers related either to the available
evidence for the effectiveness of chemoprevention, practi-
cal constraints to discussing it with women, or to percep-
tions held by clinicians about chemoprevention.
Evidence
Some felt the evidence supporting the effectiveness of che-
moprevention was not strong enough to justify recom-
mending it to their clients and the evidence was seen as
weak in several different ways (quotes 1–4, Table 2).
Another issue related to evidence was the perceived
adverse balance between benefits and side effects (quote
5, Table 2).
Quotes 6 and 7, table 2 demonstrate that another com-
mon barrier regarding evidence was the perception that
BSO was more effective than chemoprevention at reduc-
ing breast cancer risk in mutation carriers.
Practice
Clinicians also identified a number of barriers to the dis-
cussion of chemoprevention that were more practical. The
fact neither Tamoxifen nor Raloxifene is licensed in Aus-
tralia for use in chemoprevention and neither is listed for
chemoprevention on the Pharmaceutical Benefits Scheme
(PBS) acted as barriers among this group of clinicians
(quotes 8 and 9, table 2). Another barrier was that chem-
oprevention is included in Australian guidelines on man-
agement of high risk women only in terms of offering
participation in "a relevant approved clinical trial"[24]
(quotes 10 and 11, table 2).
The fact that women rarely asked about chemoprevention
also acted as a barrier for clinicians. Some clinicians relied
on women's interest to guide their discussion, as evi-
denced by the comments made by two medical oncolo-
gists in Group 1 (quotes 12 and 13, table 2)
Perception
Clinicians' perception that they were personally not
knowledgeable about chemoprevention was a further bar-
rier to recommending it to their clients (quote 14, table
Example of a response to Case Study 1 Figure 2
Example of a response to Case Study 1.
4A (medical oncologist)  …We would advise them to have their ovaries removed 
now … we are quite directive, in regards to ovaries, we 
think this is the best option … if the women prefers not 
to have the BSO and it’s very unusual …  we would 
then advise screening, on the understanding that we’ve 
no proof of its benefits … And then in terms of her 
breasts we’d be canvassing her thoughts on whether 
she’s ever considered risk reducing mastectomy… at 
the current time we don’t mention Tamoxifen as a 
prevention agent, um, mainly because it’s um--well we 
will, once we’ve got IBIS 2 up and running. So we will 
be involved in a clinical trial. It’s not licensed for use in 
the prevention context, and obviously there are side 
effects. Hereditary Cancer in Clinical Practice 2009, 7:9 http://www.hccpjournal.com/content/7/1/9
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Table 2: Barriers to the discussion of breast cancer chemoprevention in Family Cancer Centres with supporting quotes
EVIDENCE Participant No Quote
Evidence not strong enough 1A (med oncologist) 1 I don't think that there's really strong evidence to support a reduction in 
breast cancer occurrence [in BRCA1 and BRCA2 mutation carriers].
4A (med oncologist) 2 It may be effective in BRCA2 carriers, but the numbers are very small 
and so, we probably need some further evidence.
5C (med oncologist) There are no randomized trials in high risk women, truly high risk women
1C (med oncologist) 3 There's no survival benefit.
2B (gynae oncologist) 4 You may... be preventing some cancers but you may not be saving lives.
Side effects outweigh benefits 2A (breast surgeon) 5 The data would support that there is risk reduction but... at a price, of 
the side effects and complications and I don't personally think that that 
sort of balance is such to encourage people to be taking the medication.
BSO superior to chemoprevention in 
BRCA mutation carriers
5B (genetic counsellor) 6 And next the question that I don't know, and I don't think anyone does, is 
what's the benefit of Tamoxifen in addition to the benefit you're going to 
get from oophorectomy...
4A (med oncologist) 7 Because of the very high uptake – 70%, of BSOs, it doesn't routinely 
come up.
PRACTICE
Not TGA approved* for prevention 2C (gynae oncologist) 8 ..and also because it [Tamoxifen] is not approved in Australia for 
prevention, you have to pay for it..... It's not hugely expensive but it's not 
cheap. And you can tell people that it is approved in the USA for this 
purpose but not in Australia, and you can give them the facts.
Not on the PBS** for prevention 3A (clinical geneticist) 9 When the IBIS report showed Tamoxifen reduced the risk of breast 
cancer, we kept a watching brief on that as it were, but didn't pursue it in 
detail because Tamoxifen was not and is still not on the PBS.
Chemoprevention only referred to in 
national guidelines as part of clinical trials
4A (med oncologist) 10 We discuss it when the chemoprevention trials are open..... But.... once 
the IBIS I closed, we have not routinely been discussing chemoprevention 
with the unaffected woman.
5A (clinical geneticist) 11 If you go back to all of the management guidelines and look at 
the...recommendations for chemoprevention, there's very few of them 
that actually recommend it.
Not many women ask about it 1D (med oncologist) 12 Up until recently I haven't really delved into it ... unless the woman has 
appeared interested in some way.
1C (med oncologist) 13 Not many woman come forward asking questions about this.
PERCEPTION Participant No Quote
(We are) not knowledgeable about 
chemoprevention
3B (clinical geneticist) 14 Chemoprevention is talked about very little because basically we have 
very little knowledge of that' and later, 'if a woman specifically asks that 
question [I]would say, look that's not my area, go back to your oncologist.
Dialogue between
6E (clinical geneticist) and
6D (med oncologist)
15 LK Do you discuss it with people, 6E?
6E Look, pretty infrequently, that's the sort of thing that um, well if it 
does crop up it's usually because I've dragged 6D in to see my patient 
[laughs].
LK And is that because of your specialty 6D?
6D I'm an oncologist. So I would be more comfortable to discuss what 
the risks are, what the benefits are of, you know, taking Tamoxifen.
Women are opposed to hormonal 
treatment
1D (med oncologist) 16 This group as a whole are not really using any form of hormonal 
intervention, whether it be the pill, HRT or Tamoxifen, they are un-keen. 
And later: [They have had it] drummed into them right from the year 
dot, hormones are bad, hormones are bad.
* The Australian Therapeutic Goods Administration (TGA) has a similar role to the U.S. Federal Drugs Administration
**The Australian Pharmaceutical Benefits Scheme (PBS) provides subsidized pharmaceuticals to all AustraliansHereditary Cancer in Clinical Practice 2009, 7:9 http://www.hccpjournal.com/content/7/1/9
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2). This particular barrier was strongly influenced by the
clinician specialty, with oncologists expressing more con-
fidence in their knowledge about Tamoxifen than clinical
geneticists, as demonstrated during the exchange in quote
15, Table 2 between a clinical geneticist and medical
oncologist.
Clinicians also reported that women's perceptions acted
as barriers to discussing chemoprevention, specifically
negative attitudes towards hormonal treatments in gen-
eral, and chemoprevention in particular (quote 16, table
2).
Enablers to Discussing Chemoprevention
Analyzing the few instances where chemoprevention was
discussed favorably or even recommended to clients by
clinicians, it was possible to identify the things that ena-
bled the clinician to take this stance. Table 3 summarizes
the three categories of enablers, related to either evidence,
practice or perception.
Evidence
Those who recommended Tamoxifen felt that there was
reasonable evidence to support its use as a chemopreven-
tive agent for BRCA2 mutation carriers (quote 17, table 3).
One clinician (medical oncologist) also identified that the
risk/benefit ratio is more favorable in younger women
(quote 18, table 3).
Practice
A practical enabler to providing chemoprevention was
being able to offer clients enrolment in a trial. As shown
earlier, one of the medical oncologists was comfortable
placing clients on a research trial (quote 10, table 2). This
position is also consistent with the current national guide-
lines. A similar sentiment was expressed by another med-
ical oncologist (quote 19, table 3).
The fact that tamoxifen is not an expensive drug was also
identified as an enabler to prescribing (quote 20, table 3).
Perception
5C perceived the action of Tamoxifen to reduce the risk of
breast cancer for BRCA2 carriers as something that clini-
cians 'intuitively understand', and acknowledged that the
lack of 'hard data' had 'never stopped anyone doing anything'
(quotes 21 and 22, Table 3). This perception is counter to
the perception expressed by others, namely that the evi-
dence is not good enough, and that lack of evidence is a
barrier.
Discussion
Despite high quality evidence of the efficacy of Tamoxifen
and Raloxifene for breast cancer prevention, international
uptake, even among very high risk women, is much lower
than anticipated. The potential of breast cancer chemo-
prevention to improve morbidity is hence not fully real-
ized. The situation is also jeopardizing future advances in
the area. The planned NSABP-P4 trial which was to com-
pare the efficacy of Raloxifene and Letrozole in this setting
has been postponed indefinitely because, according to the
Director of the U.S. National Cancer Institute, previous
studies "while scientifically enlightening, have failed to
change the practice of breast cancer prevention among
Table 3: Enablers to the discussion of chemoprevention in Family Cancer Centres with supporting quotes
EVIDENCE Participant No Quote
'Reasonable' evidence in BRCA2 carriers 5C (med oncologist) 17 I think that in a BRCA2 mutation carrier we'll discuss Tamoxifen- I'm a bit 
more confident about Tamoxifen with a BRCA2, than in a BRCA1.
Side-effects less in younger women 1A (med oncologist) 18 ...side effects at that age [45] are likely be to be small in absolute terms
PRACTICE
Enroling people on a trial is convenient 1B (med oncologist) 19 When the IBIS I study was recruiting that would be definitely part of my 
discussion because there was a study that they could participate in to try 
and get an answer. But then that closed so there's been a window 
between now and then [-]... There's sort of been a bit of a lull.
Not expensive 5C (med oncologist) 20 identified that not being PBS-listed was not a constraint to 
prescribing Tamoxifen because it 'is not an expensive drug'
PERCEPTION
Action of Tamoxifen to reduce risk 'intuitively 
makes sense'
5C (med oncologist) 21 But intuitively, I can understand how um, Tamoxifen would reduce the 
risk.
Lack of 'hard data' is not always a barrier to 
recommending something
5C (med oncologist)
5A (clinical geneticist) 22 5A Breast ultrasound? If you're having MRI? No, but if you aren't having 
it, then, there's very little hard data...
5C I know there's no hard data but that's never stopped anyone doing 
anythingHereditary Cancer in Clinical Practice 2009, 7:9 http://www.hccpjournal.com/content/7/1/9
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women and their healthcare providers"[25]. It is therefore
critically important to understand the barriers to the dis-
cussion of breast cancer chemoprevention with high risk
women. In this study of 23 clinicians in FCCs, comprising
64% of eligible participants and 56% of clinicians who are
members of the Australian national consortium for famil-
ial breast cancer [26], we identified several barriers and
enablers to the discussion of chemoprevention with cli-
ents.
Many clinicians felt that the evidence for use of chemopre-
vention was not strong enough for them to discuss it with
their clients. While there is clear evidence from large ran-
domized controlled trials that Tamoxifen reduces breast
cancer risk by 30–50% [6-9], clinicians expressed concern
about how applicable these findings were to the popula-
tion of women that they see. Clinicians in this study were
also concerned that because a survival benefit has not
been demonstrated, the evidence was inadequate, yet they
routinely discuss mammographic and MRI screening and
risk-reducing mastectomy with their clients, strategies
where no survival benefit has been shown for this group.
Like the clinicians studied by Peshkin, clinicians in our
study were more likely to discuss chemoprevention with a
BRCA2, rather than a BRCA1, mutation carrier [19]. BRCA1
carriers (unlike BRCA2 carriers) usually develop estrogen
receptor alpha negative tumors and the randomized chem-
oprevention studies have all failed to demonstrate a
decrease in such tumors. However, estrogen may be impor-
tant in the pathogenesis of BRCA1-associated BC [27] and
tamoxifen and raloxifene may act as preventive agents in
BRCA1 carriers by binding to estrogen receptor beta [28].
BSO, a strategy embraced by many of the clinicians in the
study, reduces incidence of BRCA1-associated breast cancer
also presumably by a hormonal mechanism.
Of particular interest, clinicians in this study were more
comfortable discussing chemoprevention with BRCA2
carriers than high risk women without a demonstrated
mutation. The reason for this was unclear from the focus
group discussions, especially since BSO would not usually
be recommended to reduce breast cancer risk in the latter
group and there is stronger evidence for efficacy of chem-
oprevention in that group. Perhaps it is because high-risk
women without an identified mutation are, on average, at
lower lifetime risk for breast cancer (30–40%) than
BRCA1 and BRCA2 mutation carriers (60–80%) and thus
the balance of risks and benefits is assessed differently.
Potential side-effects of chemoprevention are an impor-
tant issue. The perception that side-effects outweighed the
benefits was expressed by clinicians in this study. Vaso-
motor and gynaecologic symptoms of women on chemo-
prevention are mostly manageable [8,9] or resolve on
cessation of therapy, but endometrial cancer and throm-
bosis are potentially serious side-effects. Endometrial can-
cer risk is not increased for pre-menopausal women, and
for post-menopausal women the risk is less with
Raloxifene compared with Tamoxifen. The excess risk of
endometrial cancer and thrombotic events respectively
have been estimated at 1 in 2686 and 1 in 1042 per year
of preventive Tamoxifen use [11]. Some, but not all,
women will consider these risks tolerable in the setting of
a 30–50% reduction in their breast cancer risk. We argue
that clinicians should not make assumptions about what
their clients will accept. Instead women should be rou-
tinely informed of the risks and benefits of chemopreven-
tion along with the other available risk management
strategies.
Similarly, clinicians cited their clients' lack of knowledge
about chemoprevention as a barrier to discussing it with
them, but until chemoprevention is discussed as an
option, it is unlikely that awareness of chemoprevention
will be increased among those eligible to use it.
The fact that Tamoxifen and Raloxifene are not licensed by
the Australian Therapeutic Goods Administration (TGA)
and not listed on the Australian PBS for the specific indi-
cation of breast cancer prevention was perceived as a bar-
rier to discussing and prescribing chemoprevention. The
Australian TGA grants marketing approval for specific
medicines for specific indications, but once a medicine is
approved for one indication (e.g. treatment of breast can-
cer) it can be prescribed 'off-label' for another. Off-label
prescribing is an accepted and common practice in oncol-
ogy [29,30]. Our study suggests that perhaps not all clini-
cians who advise high risk women are aware of off-label
prescribing, specifically, those who do little or no pre-
scribing, such as clinical geneticists and genetic coun-
selors. Alternatively, the TGA and PBS non-listed status of
Tamoxifen and Raloxifene for chemoprevention may con-
tribute to the idea that their use in this setting is not legit-
imate, rather than acting as barriers directly: in Australia,
Raloxifene costs approximately $2.25 per day, and
Tamoxifen $0.20 to $1 per day.
Off-study use of chemoprevention in this setting is sup-
ported in international guidelines [31-33], but not Aus-
tralian guidelines[24]. Our study identified this as a
barrier to its use, highlighting the importance of keeping
guidelines up to date. The Australian guidelines were pub-
lished in 1999 and do not incorporate any of the evidence
from trials published after that date, including IBIS I
[9,34]. Updated Australian guidelines, which include use
of chemoprevention as a management option have been
prepared by the authors and others but are not yet pub-
lished. Their publication and dissemination may address
several of the barriers identified in the study.Hereditary Cancer in Clinical Practice 2009, 7:9 http://www.hccpjournal.com/content/7/1/9
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In a study of Californian physicians, 40% indicated that
they did not have time to adequately discuss breast cancer
risk reduction options [20], but in our study lack of time
was not identified as a potential barrier.
This study examined the attitudes of clinicians who work
in multidisciplinary FCCs around Australia and is likely to
be representative of the attitudes of clinicians working in
that setting. Although a woman's initial risk assessment
would generally occur in such a Center, many women
receive their subsequent management from external
breast surgeons. It would be of interest to determine the
relative importance of the various barriers identified in
this and other studies among those clinicians.
Of the barriers to the discussion of breast cancer chemo-
prevention identified, those with the most straightforward
potential interventions include the maintenance of up-to-
date national guidelines on management of high-risk
women and education of clinicians about off-label pre-
scribing and the relatively low costs of chemopreventive
medications. More education about chemoprevention
options for those specialties that advise these women but
that are unfamiliar with prescribing these drugs in other
settings may also improve the likelihood that chemopre-
vention will be discussed in the consultation. Neverthe-
less women will ultimately need to weigh the potential
benefit against side-effects, and further studies on the use
of decision aids in this setting may be useful [35].
Addressing these factors may result in better acceptance of
chemoprevention by clinicians which may translate into
improved levels of uptake by high risk women.
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